Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Finished Goods (2019 - 2025)

CorMedix (CRMD) has disclosed Finished Goods for 5 consecutive years, with $14.4 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 385.98% to $14.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.4 million through Dec 2025, up 385.98% year-over-year, with the annual reading at $14.4 million for FY2025, 385.98% up from the prior year.
  • Finished Goods hit $14.4 million in Q4 2025 for CorMedix, up from $12.8 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $14.4 million in Q4 2025 to a low of $245668.0 in Q2 2021.
  • Historically, Finished Goods has averaged $3.9 million across 3 years, with a median of $1.6 million in 2024.
  • Biggest five-year swings in Finished Goods: tumbled 39.79% in 2021 and later surged 1233.22% in 2025.
  • Year by year, Finished Goods stood at $245668.0 in 2021, then skyrocketed by 1105.29% to $3.0 million in 2024, then soared by 385.98% to $14.4 million in 2025.
  • Business Quant data shows Finished Goods for CRMD at $14.4 million in Q4 2025, $12.8 million in Q3 2025, and $3.3 million in Q2 2025.